In NZ, drug applications submitted for licensing are considered by the Medicines Assessment Advi-sory Committee (MAAC), which is advisory to the Ministry of Health.
SELECTION OF MEDICINES FOR
MONITORING
In
NZ, drug applications submitted for licensing are considered by the Medicines
Assessment Advi-sory Committee (MAAC), which is advisory to the Ministry of
Health. The MAAC has traditionally made the recommendations for which drugs
should be moni-tored. For each drug recommended, the Director of the IMMP would
undertake a feasibility study that would then be considered by an expert panel
with a final recommendation then made to the Ministry of Health. The panel gave
priority to monitoring those drugs where the conditions in Table 25.1 applied.
At
the time of writing, no new medicines are being recommended for monitoring by
the IMMP. One reason for this is the planned merger of the NZ and Australian
medicines regulatory bodies and their advisory committees in 2007. Proposals
for how the new Joint Tasman Agency will monitor the safety of new medicines is
currently under development and is anticipated that the IMMP will continue to perform
targeted post-marketing studies on selected medicines.
TH 2019 - 2024 pharmacy180.com; Developed by Therithal info.